Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $19.9 million.

  • Ligand Pharmaceuticals' Other Non-Current Liabilities fell 3334.67% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 3334.67%. This contributed to the annual value of $30.2 million for FY2024, which is 866.42% up from last year.
  • Ligand Pharmaceuticals' Other Non-Current Liabilities amounted to $19.9 million in Q3 2025, which was down 3334.67% from $14.4 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $43.7 million during Q3 2023, with a 5-year trough of $14.2 million in Q1 2025.
  • Its 5-year average for Other Non-Current Liabilities is $25.6 million, with a median of $27.8 million in 2022.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 9896.12% in 2023, then plummeted by 5104.43% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $21.8 million in 2021, then grew by 27.61% to $27.8 million in 2022, then changed by 0.0% to $27.8 million in 2023, then rose by 8.66% to $30.2 million in 2024, then crashed by 33.99% to $19.9 million in 2025.
  • Its last three reported values are $19.9 million in Q3 2025, $14.4 million for Q2 2025, and $14.2 million during Q1 2025.